Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | 23,245 |
| 52 Week High | $89.15 |
| 52 Week Low | $42.00 |
| Target Price | $88.50 |
| Ticker | BSTC:UW |
| Composite Ticker | BSTC:US |
| Security Name | Biospecifics Technologies Corp. |
| Type | Ordinary Shares |
| Class | BSTC |
| Currency | USD |
| Round Lot Size | 100 |
| Primary | Yes |
| Delisted | Yes |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | Equity |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG000CLV6B9 |
| Composite FIGI | BBG000CLT0M3 |
| Share Class FIGI | BBG001S6Z1T1 |
| FIGI Unique ID | N/A |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | 1992-04-21 |
| Beta | 0.8257 |
| 1-year beta | 0.9203 |
| 3-year beta | 0.8257 |
| 5-year beta | 0.9423 |
| 7-year beta | 0.9451 |
| 10-year beta | 0.9802 |
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.
